|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 43.10 GBX | -.--% |
|
+6.42% | +9.39% |
| 06-02 | British Land Price Target Rises as Berenberg Ups Estimates on FY27 Guidance Affirmation | MT |
| 05-20 | British Land confident in office space demand as annual profit rises | AN |
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
Rental Revenues | 1.28M | 13.12M | 15.48M | 16.36M |
Other Revenues, Total | - | 2.58M | 4.46M | 3.95M |
Total Revenues | 1.28M | 15.71M | 19.94M | 20.31M |
Property Expenses | - | 4.77M | 6.12M | 5.88M |
Selling General & Admin Expenses, Total | 2M | 5.61M | 5.25M | 4.84M |
Total Operating Expenses | 2M | 10.38M | 11.37M | 10.72M |
Operating Income (REIT / Utility Template) | -725K | 5.33M | 8.58M | 9.59M |
Interest Expense, Total | - | -3.78M | -9.6M | -10.39M |
Interest and Investment Income | 16.8K | 1.1M | 3.66M | 4.01M |
Net Interest Expenses | 16.8K | -2.68M | -5.95M | -6.38M |
Other Non Operating Income (Expenses) | - | 2.16M | 152K | 195K |
EBT, Excl. Unusual Items | -708K | 4.8M | 2.78M | 3.4M |
Gain (Loss) on Sale of Assets | - | - | -317K | - |
Asset Writedown | 19.29M | -31.31M | -22.85M | -17.38M |
Other Unusual Items | - | -957K | -1.47M | - |
EBT, Incl. Unusual Items | 18.58M | -27.47M | -21.85M | -13.98M |
Income Tax Expense | - | 146K | -146K | - |
Earnings From Continuing Operations | 18.58M | -27.61M | -21.71M | -13.98M |
Net Income to Company | 18.58M | -27.61M | -21.71M | -13.98M |
Net Income - (IS) | 18.58M | -27.61M | -21.71M | -13.98M |
Net Income to Common Incl Extra Items | 18.58M | -27.61M | -21.71M | -13.98M |
Net Income to Common Excl. Extra Items | 18.58M | -27.61M | -21.71M | -13.98M |
Per Share Items | ||||
Net EPS - Basic | 0.05 | -0.08 | -0.06 | -0.04 |
Basic EPS - Continuing Operations | 0.05 | -0.08 | -0.06 | -0.04 |
Basic Weighted Average Shares Outstanding | 350M | 350M | 350M | 350M |
Net EPS - Diluted | 0.05 | -0.08 | -0.06 | -0.04 |
Diluted EPS - Continuing Operations | 0.05 | -0.08 | -0.06 | -0.04 |
Diluted Weighted Average Shares Outstanding | 350M | 350M | 350M | 350M |
Normalized Basic EPS | -0 | 0.01 | 0 | 0.01 |
Normalized Diluted EPS | -0 | 0.01 | 0 | 0.01 |
Dividend Per Share | - | 0.04 | 0.02 | 0.01 |
Payout Ratio | - | -12.68 | -64.5 | -50.08 |
Supplemental Items | ||||
EBITA | -725K | 5.33M | 8.58M | 9.59M |
EBIT | -725K | 5.33M | 8.58M | 9.59M |
Total Revenues (As Reported) | - | 15.71M | 19.94M | 20.31M |
Effective Tax Rate - (Ratio) | - | -0.53 | 0.67 | - |
Normalized Net Income | -442K | 3M | 1.74M | 2.12M |
Interest Capitalized | - | 1.8M | 3.26M | 2.09M |
Supplemental Operating Expense Items | ||||
General and Administrative Expenses | 2M | 5.61M | 5.25M | 4.84M |
Net Rental Expense, Total | - | 228K | 591K | 662K |
Imputed Operating Lease Interest Expense | - | - | 559K | 574K |
Imputed Operating Lease Depreciation | - | - | 32.37K | 87.84K |
- Stock Market
- Stocks
- LABS Stock
- Financials Life Science REIT plc
- Income Statement
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















